查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1593862

肝病治療市場：按治療方法、最終用戶分類 - 2025-2030 年全球預測

Liver Diseases Therapeutics Market by Treatment (Anti Viral Drugs, Chemotherapy Drugs, Corticosteroids), End User (Ambulatory Surgery Centers, Hospitals) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年肝病治療市場規模為167.7億美元，預計2024年將達181.2億美元，複合年成長率為8.16%，2030年將達290.4億美元。

肝病治療市場包括開發和使用藥物和治療方法來治療各種肝病，例如肝炎、肝癌和肝硬化。全球肝臟疾病盛行率不斷上升，推動了對這些治療的需求，而飲酒、肥胖和肝炎感染增加等生活方式因素往往會加劇這種疾病。治療是在預防、治療和支持性護理的框架內進行的，最終用戶包括醫院、臨床研究中心和門診病人設施。關鍵的成長要素包括藥物治療的進步、對肝病病理生理學的更好理解以及新興市場醫療保健服務的擴展。精準醫療和個人化治療的採用、生物技術的使用以及協作研發的推廣存在潛在的商機。阻礙市場成長的挑戰包括高昂的治療成本、肝病發病機制的複雜性以及與藥物核准相關的監管障礙。此外，低收入地區的醫療保健基礎設施薄弱，限制了治療的獲得和接受度。在技​​術創新方面，具有成長潛力的研究領域包括生技藥品、基因治療和針對肝功能恢復的再生醫學方法。探索非侵入性診斷工具並利用巨量資料分析進行個人化治療計劃也可以提供競爭優勢。市場動態是不穩定的，競爭格局受到製藥進步、合併和策略聯盟的影響。這個廣闊而複雜的市場需要持續的投資和透徹的了解，才能有效地利用新的治療方法突破。為了緩解限制，相關人員應專注於具有成本效益的藥物開發、穩健的臨床試驗和加強病患教育，以降低疾病進展率。加強製藥公司、學術機構和政府之間的合作將對克服現有障礙和創造永續的市場環境發揮至關重要的作用。整合最新創新並響應市場需求的適應性業務策略，同時優先考慮監管合規性和道德考慮，對於肝病治療業務的持續成長仍然至關重要。

主要市場統計
基準年[2023] 167.7億美元
預測年份 [2024] 181.2億美元
預測年份 [2030] 290.4億美元
複合年成長率（%） 8.16%

市場動態：快速發展的肝病治療市場的關鍵市場洞察

供需的動態交互作用正在改變肝病治療市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球肝病迅速增加
    • 政府和私人組織加強提高意識和疫苗接種計劃
    • 生活方式的改變，例如飲酒和吸煙
  • 市場限制因素
    • 對藥物副作用的擔憂
  • 市場機會
    • 預防和治療肝病的持續研究和開發活動
    • 治療藥物專利到期增加
  • 市場挑戰
    • 與嚴格的政府法規和研發相關的高成本

波特五力：駕馭肝病治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解肝病治療市場的外部影響

外部宏觀環境因素在塑造肝病治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解肝病治療市場的競爭狀況

肝病治療市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣肝病治療市場供應商的績效評估

FPNV定位矩陣是評估肝病治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，以規劃肝病治療市場的成功之路

肝病治療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球肝病發生率飆升
      • 政府和私人組織加強宣傳和疫苗接種計劃
      • 生活方式的改變，例如飲酒和吸煙
    • 抑制因素
      • 對可能的藥物副作用的擔憂
    • 機會
      • 預防和治療肝病的持續研究和開發活動
      • 治療藥物專利到期增加
    • 任務
      • 嚴格的政府監管和高昂的研發成本
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療方式分類的肝病治療市場

  • 抗病毒藥物
  • 化療藥物
  • 皮質類固醇
  • 免疫球蛋白
  • 免疫抑制藥物
  • 標靶治療

第7章肝病治療市場：依最終使用者分類

  • 門診手術中心
  • 醫院

第8章北美與南美洲肝病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區肝病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲的肝病治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Dicerna Pharmaceuticals, Inc.
  • Endo International PLC
  • F. Hoffmann-La Roche AG
  • Gilead Science Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Protagonist Therapeutics, Inc.
  • Sanofi SA
Product Code: MRR-437A5D08AE2A

The Liver Diseases Therapeutics Market was valued at USD 16.77 billion in 2023, expected to reach USD 18.12 billion in 2024, and is projected to grow at a CAGR of 8.16%, to USD 29.04 billion by 2030.

The liver diseases therapeutics market involves the development and use of drugs and treatments to address a range of liver conditions, including hepatitis, liver cancer, and cirrhosis, among others. The necessity for these therapeutics is driven by the rising prevalence of liver conditions globally, often exacerbated by lifestyle factors such as alcohol consumption, obesity, and the increasing incidence of hepatitis infections. Applications span across preventive, curative, and supportive treatment frameworks, with end-users including hospitals, clinical research centers, and outpatient facilities. Key growth factors include advancements in pharmacotherapy, an increased understanding of liver disease pathophysiology, and expanding healthcare access in emerging markets. Potential opportunities lie in adopting precision medicine and personalized therapeutics, leveraging biotechnology, and pursuing collaborations for research development. Challenges impeding market growth include high treatment costs, the complexity of liver disease etiology, and regulatory hurdles associated with drug approval. Moreover, inconsistent healthcare infrastructure in low-income regions limits therapeutic accessibility and adoption. For innovation, research areas promising growth prospects include biologics, gene therapy, and regenerative medicine approaches targeting liver function restoration. Exploring non-invasive diagnostic tools and leveraging big data analytics for personalized treatment plans can also offer competitive advantages. Market dynamics are fluid, with competitive landscapes influenced by pharmaceutical advancements, mergers, and strategic partnerships. This broad and complex market requires ongoing investment and thorough understanding to capitalize on emerging therapeutic breakthroughs effectively. To mitigate limitations, stakeholders should focus on cost-effective drug development, robust clinical trials, and enhancing patient education to reduce disease progression rates. Enhanced collaboration among pharma companies, academic institutions, and governments will play a crucial role in overcoming existing barriers and creating a sustainable market environment. An adaptable business strategy, which integrates recent innovations and responds to market needs while prioritizing regulatory compliance and ethical considerations, remains pivotal for sustained business growth in liver diseases therapeutics.

KEY MARKET STATISTICS
Base Year [2023] USD 16.77 billion
Estimated Year [2024] USD 18.12 billion
Forecast Year [2030] USD 29.04 billion
CAGR (%) 8.16%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Liver Diseases Therapeutics Market

The Liver Diseases Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surge in the incidences of liver diseases worldwide
    • Increasing government and private organizations initiatives toward awareness and vaccination programs
    • Changing lifestyles such as consumption of alcohol and smoking
  • Market Restraints
    • Concerns over probable side effects of the medication
  • Market Opportunities
    • Ongoing research and development activities for prevention and cure of liver diseases
    • Increasing patent expiration of therapeutics
  • Market Challenges
    • Strict government regulations and high cost involved in R&D

Porter's Five Forces: A Strategic Tool for Navigating the Liver Diseases Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Liver Diseases Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Liver Diseases Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Liver Diseases Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Liver Diseases Therapeutics Market

A detailed market share analysis in the Liver Diseases Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Liver Diseases Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Liver Diseases Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Liver Diseases Therapeutics Market

A strategic analysis of the Liver Diseases Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Liver Diseases Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Dicerna Pharmaceuticals, Inc., Endo International PLC, F. Hoffmann-La Roche AG, Gilead Science Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., Protagonist Therapeutics, Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Liver Diseases Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Anti Viral Drugs, Chemotherapy Drugs, Corticosteroids, Immunoglobulin, Immunosuppressant Drugs, and Targeted Therapy.
  • Based on End User, market is studied across Ambulatory Surgery Centers and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surge in the incidences of liver diseases worldwide
      • 5.1.1.2. Increasing government and private organizations initiatives toward awareness and vaccination programs
      • 5.1.1.3. Changing lifestyles such as consumption of alcohol and smoking
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns over probable side effects of the medication
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development activities for prevention and cure of liver diseases
      • 5.1.3.2. Increasing patent expiration of therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Strict government regulations and high cost involved in R&D
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Liver Diseases Therapeutics Market, by Treatment

  • 6.1. Introduction
  • 6.2. Anti Viral Drugs
  • 6.3. Chemotherapy Drugs
  • 6.4. Corticosteroids
  • 6.5. Immunoglobulin
  • 6.6. Immunosuppressant Drugs
  • 6.7. Targeted Therapy

7. Liver Diseases Therapeutics Market, by End User

  • 7.1. Introduction
  • 7.2. Ambulatory Surgery Centers
  • 7.3. Hospitals

8. Americas Liver Diseases Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Liver Diseases Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Liver Diseases Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astellas Pharma Inc.
  • 2. AstraZeneca PLC
  • 3. Bayer AG
  • 4. Bristol-Myers Squibb Company
  • 5. Dicerna Pharmaceuticals, Inc.
  • 6. Endo International PLC
  • 7. F. Hoffmann-La Roche AG
  • 8. Gilead Science Inc.
  • 9. GlaxoSmithKline PLC
  • 10. Johnson & Johnson Services, Inc.
  • 11. Merck & Co. Inc.
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Protagonist Therapeutics, Inc.
  • 15. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. LIVER DISEASES THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. LIVER DISEASES THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. LIVER DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LIVER DISEASES THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LIVER DISEASES THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTI VIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANT DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 104. LIVER DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023